0
0.5
1
1.5
2+
Mortality
-58%
Improvement
Relative Risk
Mortality, fluoxetine
26%
Fluvoxamine for COVID-19 Oskotsky et al. Prophylaxis
Is prophylaxis with fluvoxamine beneficial for COVID-19?
PSM retrospective 7,696 patients in the USA
Study underpowed for fluvoxamine, only 11 patients
c19early.org
Oskotsky et al., JAMA Network Open, Nov 2021
Favors fluvoxamine
Favors control